Last viewed:
NVSEF
Prices are updated after-hours
NVSEF
|
News
|
$96.0
6.88%
52K
|
Health Technology
(0.0% 1d)
(0.3% 1m)
(10.3% 1y)
(0.0% 2d)
(0.9% 3d)
(6.4% 7d)
(10458.54%
volume)
Earnings Calendar:
Market Cap: $ 213,036,438,720
http://www.novartis.com
Sec
Filling
|
Patents
| n/a employees
(CH) Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
add to watch list
Paper trade
email alert is off
Press-releases
Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria
Published: 2024-04-24
(Crawled : 05:00)
- globenewswire.com
NVS
|
News
|
$98.35
1.1%
0.0%
2.2M
|
Health Technology
| 0.0%
| O: -0.49%
H: 0.0%
C: 0.0%
malaria
positive
treatment
for
novartis
Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors
Published: 2024-04-23
(Crawled : 18:00)
- globenewswire.com
NVSEF
|
News
|
$96.0
6.88%
52K
|
Health Technology
| 0.94%
| O: 1.69%
H: 0.02%
C: -0.74%
NVS
|
News
|
$98.35
1.1%
0.0%
2.2M
|
Health Technology
| 4.32%
| O: 4.32%
H: 0.0%
C: 0.0%
lutathera
fda
first
approved
tumors
for
novartis
therapy
Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised
Published: 2024-04-23
(Crawled : 05:00)
- globenewswire.com
NVSEF
|
News
|
$96.0
6.88%
52K
|
Health Technology
| 0.94%
| O: 1.69%
H: 0.02%
C: -0.74%
NVS
|
News
|
$98.35
1.1%
0.0%
2.2M
|
Health Technology
| 4.32%
| O: 4.32%
H: 0.0%
C: 0.0%
MOR
|
News
|
$18.07
0.17%
0.17%
130K
|
Health Technology
| 0.39%
| O: 0.39%
H: 0.0%
C: 0.0%
sales
expansion
novartis
growth
Over-The-Counter Drug Market size is set to grow by USD 58.54 billion from 2023-2027, Abbott Laboratories, Achelios Therapeutics Inc. and AstraZeneca Plc, and more to emerge as Some of the Key Vendors, Technavio
Published: 2024-04-22
(Crawled : 22:00)
- prnewswire.com
RBGPF
|
News
|
$52.06
6.46%
4.8K
|
Consumer Non-Durables
| 0.08%
| O: 0.98%
H: 5.46%
C: -0.89%
GLAXF
|
News
|
$19.54
-14.18%
2.6K
|
Health Technology
| -3.74%
| O: -3.15%
H: 0.0%
C: -0.61%
AZNCF
|
News
|
$140.3
-4.19%
1.5K
|
Health Technology
| 1.13%
| O: 0.96%
H: 2.38%
C: 0.17%
NVSEF
|
News
|
$96.0
6.88%
52K
|
Health Technology
| 0.94%
| O: 1.69%
H: 0.02%
C: -0.74%
RBGLY
|
News
|
$10.59
-2.05%
850K
|
Manufacturing
| 1.7%
| O: -0.28%
H: 2.18%
C: 1.99%
NVS
|
News
|
$98.35
1.1%
0.0%
2.2M
|
Health Technology
| 4.32%
| O: 4.32%
H: 0.0%
C: 0.0%
GSK
|
News
|
$40.86
-0.92%
-0.15%
1.7M
|
Health Technology
| 1.6%
| O: 0.17%
H: 1.48%
C: 1.43%
ABT
|
News
|
$106.89
-0.65%
-0.22%
5.1M
|
Health Technology
| 0.49%
| O: 0.56%
H: 0.41%
C: -0.07%
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
| 1.7%
| O: 1.7%
H: 0.0%
C: 0.0%
AZN
|
News
|
$71.175
0.46%
0.46%
6.1M
|
Health Technology
| 1.03%
| O: 0.4%
H: 0.0%
C: 0.0%
drug
astrazeneca
set
key
therapeutics
market
Viral Vector and Plasmid DNA Technologies: A Global Market Perspective
Published: 2024-04-17
(Crawled : 10:00)
- prnewswire.com
TMO
|
News
|
$577.39
0.49%
0.0%
2M
|
Health Technology
| 1.46%
| O: -0.26%
H: 0.03%
C: -1.55%
NVS
|
News
|
$98.35
1.1%
0.0%
2.2M
|
Health Technology
| 6.51%
| O: 0.87%
H: 0.16%
C: -0.59%
RGNX
|
$16.05
0.94%
0.93%
350K
|
Health Technology
| -10.9%
| O: -1.43%
H: 2.27%
C: -3.18%
global
dna
market
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis
Published: 2024-04-17
(Crawled : 06:00)
- globenewswire.com
NVS
|
News
|
$98.35
1.1%
0.0%
2.2M
|
Health Technology
| 6.51%
| O: 0.87%
H: 0.16%
C: -0.59%
kesimpta
sclerosis
novartis
show
benefits
Emphysema Treatment Market to Reach $8.7 Billion, Globally, by 2032 at 3.3% CAGR: Allied Market Research
Published: 2024-04-16
(Crawled : 14:00)
- prnewswire.com
VTRS
|
News
A
|
$11.55
1.67%
1.65%
7.2M
|
Health Technology
| 0.35%
| O: -0.53%
H: 0.0%
C: -1.24%
NVS
|
News
|
$98.35
1.1%
0.0%
2.2M
|
Health Technology
| 4.95%
| O: -1.46%
H: 0.0%
C: 0.0%
PHG
|
News
|
$20.97
-0.19%
0.0%
650K
|
Health Technology
| 1.64%
| O: -1.21%
H: 0.0%
C: 0.0%
GSK
|
News
|
$40.86
-0.92%
-0.15%
1.7M
|
Health Technology
| 1.83%
| O: -1.19%
H: 0.52%
C: -0.17%
VRNA
|
$15.21
-2.44%
-2.5%
320K
|
Health Technology
| -1.33%
| O: 1.65%
H: 2.43%
C: 0.87%
reach
treatment
research
market
Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders
Published: 2024-04-16
(Crawled : 11:00)
- globenewswire.com
NVS
|
News
|
$98.35
1.1%
0.0%
2.2M
|
Health Technology
| 4.95%
| O: -1.46%
H: 0.0%
C: 0.0%
REGN
|
News
|
$906.55
-0.09%
-0.08%
370K
|
Health Technology
| -0.84%
| O: -1.94%
H: 0.43%
C: -0.34%
OCUL
|
News
|
$4.645
-7.1%
-7.64%
3.9M
|
Health Technology
| -35.4%
| O: -1.03%
H: 3.66%
C: 1.7%
ocular
key
leaders
Biologic Therapeutics Market size is set to grow by USD 286.12 billion from 2023-2027, Introduction of biosimilars boost the market, Technavio
Published: 2024-04-15
(Crawled : 22:00)
- prnewswire.com
SNYNF
|
News
|
$94.25
-2.18%
480
|
Health Technology
| 1.38%
| O: -1.75%
H: 0.85%
C: 0.85%
AZNCF
|
News
|
$140.3
-4.19%
1.5K
|
Health Technology
| 3.21%
| O: 2.1%
H: 0.0%
C: -2.52%
NVS
|
News
|
$98.35
1.1%
0.0%
2.2M
|
Health Technology
| 4.95%
| O: -1.46%
H: 0.0%
C: 0.0%
GSK
|
News
|
$40.86
-0.92%
-0.15%
1.7M
|
Health Technology
| 1.83%
| O: -1.19%
H: 0.52%
C: -0.17%
BAX
|
$40.93
-0.22%
0.0%
2.2M
|
Health Technology
| 2.45%
| O: -0.1%
H: 0.13%
C: -1.08%
ABBV
|
News
|
$167.8
-1.03%
-0.06%
4.1M
|
Health Technology
| 4.87%
| O: 0.32%
H: 0.96%
C: 0.22%
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
| 0.41%
| O: -2.13%
H: 0.0%
C: 0.0%
BMRN
|
$91.25
-0.88%
-0.89%
1.6M
|
Health Technology
| 0.6%
| O: -0.72%
H: 0.0%
C: 0.0%
AZN
|
News
|
$71.175
0.46%
0.46%
6.1M
|
Health Technology
| 3.08%
| O: -0.64%
H: 0.45%
C: -0.04%
AMGN
|
News
|
$273.085
-0.17%
-0.17%
2.5M
|
Health Technology
| 3.02%
| O: 0.41%
H: 0.0%
C: 0.0%
set
therapeutics
market
New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)
Published: 2024-04-15
(Crawled : 18:00)
- globenewswire.com
NVS
|
News
|
$98.35
1.1%
0.0%
2.2M
|
Health Technology
| 4.95%
| O: -1.46%
H: 0.0%
C: 0.0%
fabhalta
nephropathy
for
novartis
show
See all
Last 15 days Sec forms
File Id
Form
Published Date
Transaction Date
Direction
Code
Amount Transacted
Owned Amount